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Gliomas are the most common malignant primary brain tumors 
that arise within the central nervous sys-tem in adults and they 
account for more than 80% of  all brain tumors (Central Brain 
Tumor Registry of  the United States [CBTRUS] http://www.cb-
trus.org/).
These tumors remain difficult to treat because of  the infiltrative 
growth of  the tumor cells, and their resist-ance to standard ther-
apy. Glioblastoma Multiforme (WHO grade IV) is the most ag-
gressive of  the gliomas, accounts for nearly 60-70% of  malignant 
gliomas. A common approach for the treatment of  GBM involves 
surgery, radiation therapy, and various chemotherapeu-tic regi-
mens [1,2]. Despite advance standard therapy, including surgical 
resection followed by radiation and chemotherapy, the prognosis 
for patients with GBM remains poor. Even patients who are op-
timally treated with combined multimodal treatments have a me-
dian survival of  only 12 months. This is possibly because of  the 
poor drug delivery and the correspondingly lim-ited therapeutic 
response caused by partly intact blood brain barrier (BBB) and 
blood-tumor barrier (BTB).
Poor drug delivery significantly impairs the efficacy of  chemo-
therapy. Thus, the main challenge of  the exist-ing brain cancer 
therapies is enhancing the delivery of  chemotherapeutic agents 
selectively to the tumor by noninvasive biochemical modification 
of  the BBB/BTB [3,4].
The therapeutic efficacy of  many potent anticancer drugs is lim-
ited by their poor penetration into brain tu-mor tissue and by their 
adverse effects on healthy cells, which limits the dose of  drug 
that can be safely admin-istered to cancer patients. Invasive drug 
delivery strat-egies circumvent the BTB but require either a crani-
otomy or insertion of  catheters into the carotid artery. Research 
in brain tumors should focus on strategies for improving non-
invasive drug delivery to tumors. The cerebral microvessels and 
capillaries that form the BBB protect brain but they also pose an 
obstacle to the drug delivery. Microvessels supplying brain tumors 
retain some characteristics of  BBB and form a blood brain tumor 
barrier and this BTB further significantly limits the delivery of  
chemotherapeutic drugs to tu-mors even though it is more per-
meable than BBB. Therefore, understanding biochemical mod-
ulation of  BBB and BTB is critical for developing strategies to 
deliver therapeutic agents to tumors. During the past decade a 
considerable effort has been made on the role of  certain vasoac-
tive molecules on BBB/BTB permea-bility. Vasoactive molecules 
such as leukotriene, bradykinin and certain potassium channel 
agonists selectively increase permeability in brain tumor capillar-
ies. These research ideas are being translated into strategies to in-
crease drug delivery selectively to brain tumor tissue in patients in 
clinical studies. The modulation of  critical molecules involved in 
selectively increasing BTB per-meability could lead to the devel-
opment of  effective strategy to increase chemotherapy delivery 
to tumors by noninvasive methods. BTB expresses certain unique 
protein markers that are absent or barely detectable in normal 
brain capillaries and one such marker is large conductance, cal-
cium activated potassium (BK) chan-nel. Scientists can utilize 
selectively overexpressed BK channels to modulate the BTB to 
deliver the anticancer agents selectively to tumors.
BK channels play important roles in vital cellular sign-aling pro-
cesses in both excitable and non-excitable cells. These channels 
are essential for cell prolifera-tion and appear to play a role in 
the development of  cancer. BK channels are activated by both 
membrane depolarization and micromolar levels of  intracellular 
calcium providing a link between the metabolic and electrical state 
of  cells. BK channels are also present in cerebral blood vessels 
where they regulate blood vessel tone and probably BBB and 
BTB permeability. Recent studies suggest that BK channels are 
over-expressed in primary brain tumors and tumor microvessels 
[5]. These channels respond to agonist such as NS1619 (al-pha-
subunit-selective BK opener; synthetic benzimida-zolone analog) 
[6], which selectively increase BTB per-meability to obtain sus-
tained enhancement of  selective drug delivery to brain tumors. 
This strategy exploits the responsiveness of  brain tumor capillary 
endothelial cells that over-express these channels to specific acti-
vators such as NS1619. According to recent findings
NS1619 induce accelerated formation of  transport vesicles in 
both brain tumor capillary endothelium and tumor cells. This 
mechanism allows chemotherapeutic agents to pass through 
BTB. Therefore, BK channels are potential promising targets for 
biochemical modu-lation for BTB permeability. The use of  BK 
channels as therapeutic target for brain cancer is not designed 
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to stop the cancer cell growth; instead these agents will help the 
anticancer drug penetrate deep inside the tu-mor area by opening 
them in tumor environment se-lectively. This tumor specific de-
livery will minimize the toxicity to normal cells. Thus, the use of  
BK chan-nel activators in combination with other therapies could 
improve the brain cancer treatment if  scientists provide selective 
and very potent BK activators. BK channels still considered as 
novel area of  research in glioma and we hope that scientists will 
identify the highly potent BK activator that could be used to im-
prove antiglioma agents to deliver across BBB/BTB selectively. A 
critical point is the delivery of  drug to the glioma tumor. We be-
lieve that potent BK activa-tors will further enhance significantly 
the efficacy of  antiglioma agents in tumor environment resulting 
in much improved treatment of  the disease and life ex-pectancy 
of  the brain cancer patients. An additional important considera-
tion for brain cancer research in the future will be a focus on 
chemotherapy of  both glioma and glioma stem cells (GSCs).
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